<DOC>
	<DOCNO>NCT02941679</DOCNO>
	<brief_summary>A phase 3 study evaluate efficacy safety HCP1202</brief_summary>
	<brief_title>Clinical Efficacy Safety Evaluation HCP1202 COPD Patients</brief_title>
	<detailed_description>This study design multi-center , double-blinded , randomize , phase 3 clinical trial evaluate efficacy safety HCP1202 compare either treatment HGP1011 HCP0910 COPD patient .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male Female adult age ≥ 40 year . Patients diagnose COPD . Patients FEV1/FVC &lt; 0.7 screening . Patients postbronchodilator FEV1 &lt; 60 % predict normal OR Patients postbronchodilator FEV1 &lt; 80 % predict normal COPD exacerbation moderate bad develop least twice within past year hospitalization occur least within past year due COPD exacerbation . Patients COPD Assessment Test ≥ 10 . Patients history ( current exsmokers ) smoke 10 packyears ( e.g . 10 pack year = 1 pack/day x 10 year , ½ pack/day x 20 year ) . Patients understand process clinical trial sign write informed consent . Patients current diagnosis asthma . Patients follow lung disorder affect clinical trial , except COPD : lung cancer , interstitial lung disease , thromboembolic pulmonary disease , moderate severe bronchiectasis , sarcoidosis , pulmonary fibrosis , pulmonary hypertension , active tuberculosis , clinically significant tuberculous destroy lung , alpha1antitrypsin deficiency , etc . Patients underwent pulmonary lobectomy lung volume reduction surgery within past year . Patients develop COPD exacerbation antibiotic and/or systemic corticosteroid and/or hospitalization advisable within 4 week prior Visit 1 Runin period ( , rescreening possible 4 week resolution COPD exacerbation occur within 4 week prior Visit 1 ) . Patients administer antibiotic low respiratory infection within 4 week prior Visit 1 Runin period ( , rescreening possible 4 week resolution COPD exacerbation occur within 4 week prior Visit 1 ) . Patients change COPD treatment method within 12 week prior Visit 1 ( , PDE4 inhibitor use 4 week prior Visit 1 ) . Patients administer systemic corticosteroid within 4 week prior Visit 1 . Patients follow clinically significant cardiovascular disease : history myocardial infarction unstable angina within 6 month prior Visit 1 , history unstable arrhythmia therapy method change within 1 year prior Visit 1 , history hospitalization NYHA Class IIIIV heart failure , history atrial fibrillation , negative cardiac tachycardia , and/or hypertrophic cardiomyopathy . Patients history long QTc syndrome . Patients clinical significance ECG abnormality screening ( QTc ( F ) ≥ 470 m ) . Patients require longterm oxygen therapy 12 hour day . Patients participate acute respiratory rehabilitation within 6 month prior Visit 1 ( except patient stabilized respiratory rehabilitation therapy least 6 week ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>